GleamWall
中文EN

EXEL EXELIXIS, INC.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 939767 · Fiscal year ends 01/01

Financial factors as of 2026-10-02 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY9.1%
TTM net income YoY30.6%
TTM EPS YoY40.3%
Revenue 3-yr CAGR12.1%
Net income 3-yr CAGR112.6%

Margins

Gross margin96.3%
Operating margin40.2%
Net margin35.5%
FCF margin46.5%
EBITDA margin41.3%

Returns

ROE44.3%
ROA33.2%
ROIC (approx.)47.8%
Asset turnover0.94x

Leverage & solvency

Liabilities / assets27.0%
Debt / equity0.00x
Current ratio3.21x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.33x
Accruals ratio-10.8%
Payout ratio—
Capex / revenue0.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-10-022026Q22026-07-032026Q12026-04-032025Q4*2026-01-022025Q32025-10-032025Q22025-07-042025Q12025-04-042024Q4*2025-01-03
Income statement
Revenue$658.70M$628.69M$610.81M$598.66M$597.75M$568.26M$555.45M$566.75M
Cost of revenue$26.23M$20.66M$19.95M$26.48M$18.57M$19.47M$19.17M$19.96M
Gross profit$632.46M$608.03M$590.86M$572.18M$579.18M$548.79M$536.27M$546.79M
R&D expense$209.48M$211.99M$199.92M$213.25M$199.16M$200.36M$212.23M$249.00M
SG&A expense$154.56M$147.63M$139.60M$123.02M$123.66M$134.86M$137.18M$134.33M
Operating income$268.42M$248.41M$251.34M$235.22M$236.54M$213.58M$186.86M$163.21M
Income tax$64.69M$50.63M$57.22M$8.16M$58.84M$45.57M$46.07M$44.91M
Net income$218.09M$212.05M$210.47M$244.53M$193.58M$184.85M$159.62M$139.86M
EBITDA$275.36M$255.40M$258.29M$242.16M$243.96M$220.92M$194.20M$170.85M
EPS (basic)0.880.850.81—0.720.680.57—
EPS (diluted)0.850.820.79—0.690.650.55—
Weighted avg. shares (diluted)255.75M259.68M267.32M—278.54M284.39M288.18M—
Balance sheet
Cash & equivalents$304.77M$281.45M$226.15M$482.49M$376.30M$164.43M$183.75M$217.37M
Short-term investments$587.24M$557.94M$551.05M$576.60M$612.24M$626.66M$847.56M$893.90M
Receivables$328.47M$322.21M$328.95M$286.92M$309.73M$292.35M$281.64M$265.44M
Inventory$29.87M$28.73M$26.61M$21.69M$27.40M$23.48M$24.85M$22.39M
Current assets$1.32B$1.25B$1.21B$1.44B$1.40B$1.18B$1.40B$1.47B
PP&E, net$87.28M$92.67M$95.52M$98.96M$104.75M$110.31M$115.03M$119.39M
Goodwill$63.68M$63.68M$63.68M$63.68M$63.68M$63.68M$63.68M$63.68M
Total assets$2.51B$2.49B$2.59B$2.84B$2.82B$2.68B$2.84B$2.95B
Current liabilities$411.88M$361.93M$370.98M$405.64M$373.78M$336.11M$399.10M$403.77M
Total liabilities$679.66M$650.47M$657.85M$683.10M$662.85M$644.54M$706.22M$703.49M
Shareholders' equity$1.83B$1.84B$1.94B$2.16B$2.16B$2.03B$2.13B$2.24B
Shares outstanding244.68M248.88M253.70M262.48M268.10M270.13M275.03M281.73M
Cash flow statement
Operating cash flow$279.96M$307.74M$251.84M$333.51M$290.32M$48.99M$211.44M$240.26M
Capital expenditure$2.49M$6.82M$1.51M$1.16M$1.48M$2.84M$2.95M$3.98M
Free cash flow$277.47M$300.93M$250.34M$332.36M$288.84M$46.16M$208.49M$236.29M
Investing cash flow-$6.71M$91.43M-$51.07M$27.24M$25.41M$248.03M$49.76M-$93.20M
Financing cash flow-$249.92M-$343.88M-$457.11M-$254.57M-$103.86M-$316.34M-$294.82M-$188.03M
Depreciation & amortization$6.93M$6.98M$6.95M$6.95M$7.42M$7.34M$7.34M$7.64M
Stock-based compensation$28.72M$32.56M$29.05M$20.10M$30.89M$36.07M$25.93M$26.35M
Share buybacks$249.96M$322.97M$430.35M$257.62M$104.03M$301.92M$283.93M$190.41M

Free plan shows the latest 8 periods; Pro shows all 74 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.